Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 9/20 | 0.37 |
| ▸ | MME | P08473 | 7/20 | 0.37 |
| ▸ | CPA1 | P15085 | 7/20 | 0.37 |
| ▸ | ACE2 | Q9BYF1 | 7/20 | 0.37 |
| ▸ | ECE1 | P42892 | 4/20 | 0.35 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.34 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.33 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.33 |
| ▸ | ITGAL | P20701 | 1/20 | 0.33 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.33 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.33 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7056934 | 0.91 | MAPT (0.36) | — | |
| SCHEMBL7049829 | 0.84 | MME (0.41) | ACEMMECPA1ACE2ECE1 | |
| SCHEMBL8896490 | 0.74 | ACE (0.41) | ACEMMECPA1ACE2ECE1 | |
| SCHEMBL9473540 | 0.74 | TP53 (0.35) | GPR132ITGB1ITGA4ITGB7 | |
| SCHEMBL7386107 | 0.74 | SMN1; SMN2 (0.39) | — | |
| SCHEMBL8957110 | 0.72 | MME (0.35) | ACEMMECPA1ACE2 | |
| SCHEMBL10826319 | 0.72 | CYP3A4 (0.49) | ACEMMECPA1ACE2 | |
| SCHEMBL10687059 | 0.71 | ACE (0.40) | ACEMMECPA1ACE2ECE1 | |
| SCHEMBL10506297 | 0.71 | ACE (0.40) | ACEMMECPA1ACE2ECE1 | |
| SCHEMBL10687094 | 0.71 | ACE (0.40) | ACEMMECPA1ACE2ECE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5565480-A | ANGIOTENSIN II RECEPTOR ANTAGONIST; USEFUL IN REGULATING HYPERTENSION, TREATMENT OF CONGESTIVE HEART FAILURE, RENAL FAILURE AND GLUCOMA | SMITHKLINE BEECHAM CORPORATION (US) | 1996-10-15 | — | — | US | claimed |
| EP-0536262-A4 | SUBSTITUTED HISTIDINES | SMITHKLINE BEECHAM CORP (US) | 1996-08-14 | — | — | EP | claimed |
| US-5444081-A | Treatment of hypertension, congestive heart failure, renal failure, glaucoma | SMITHKLINE BEECHAM CORP (US) | 1995-08-22 | — | — | US | claimed |
| EP-0536262-A1 | SUBSTITUTED HISTIDINES | SMITHKLINE BEECHAM CORPORATION (US) | 1993-04-14 | — | — | EP | claimed |
| WO-1992000068-A1 | SUBSTITUTED HISTIDINES | SMITHKLINE BEECHAM CORPORATION (US) | 1992-01-09 | — | — | WO | claimed |
| US-20030187044-A1 | Medicament | SMITHKLINE BEECHAM P.L.C. | 2003-10-02 | — | — | US | disclosed |
| US-20030166700-A1 | Administering a substituted imidazoles to a mammal for the treatment of athroma progression and regression | SMITHKLINE BEECHAM P.L.C. | 2003-09-04 | — | — | US | disclosed |
| US-20030096851-A1 | Medicament | SMITHKLINE BEECHAM P.L.C. | 2003-05-22 | — | — | US | disclosed |
| EP-0724387-B1 | ANGIOTENSION II RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CHRONIC ANTI-INFLAMMATORY DISEASES | SMITHKLINE BEECHAM CORP (US) | 2003-05-02 | — | — | EP | disclosed |
| US-20030069293-A1 | Medicament | SMITHKLINE BEECHAM PLC | 2003-04-10 | — | — | US | disclosed |
| US-20030050285-A1 | Substituted imidazoles; angiotensin II receptor antagonist for the treatment of hemorrhagic stroke | SMITHKLINE BEECHAM P.L.C. | 2003-03-13 | — | — | US | disclosed |
| US-20030004201-A1 | Medicament | SMITHKLINE BEECHAM P.L.C. | 2003-01-02 | — | — | US | disclosed |
| WO-1992010183-A1 | USE OF ANGIOTENSIN II RECEPTOR ANTAGONISTS IN THE TREATMENT OF DIABETIC RETINOPATHY | SMITHKLINE BEECHAM PLC (GB) | 1992-06-25 | — | — | WO | disclosed |
| WO-1992010186-A1 | USE OF ANGIOTENSN II RECEPTOR ANTAGONISTS FOR THE PREPARATION OF A MEDICAMENT FOR IMPROVING COGNITIVE FUNCTION | SMITHKLINE BEECHAM PLC (GB) | 1992-06-25 | — | — | WO | disclosed |
| WO-1992010185-A1 | USE OF ANGIOTENSIN II RECEPTOR ANTAGONISTS IN THE PREVENTION OF RESTINOSIS | SMITHKLINE BEECHAM PLC (GB) | 1992-06-25 | — | — | WO | disclosed |
| WO-1992010097-A1 | ANGIOTENSIN II RECEPTOR BLOCKING COMPOSITIONS | SMITHKLINE BEECHAM CORPORATION (US) | 1992-06-25 | — | — | WO | disclosed |
| WO-1992010184-A1 | USE OF ANGIOTENSIN II RECEPTOR ANTAGONISTS IN THE TREATMENT OF ATHEROMA | SMITHKLINE BEECHAM PLC (GB) | 1992-06-25 | — | — | WO | disclosed |
| WO-1992010182-A1 | USE OF ANGIOTENSIN II RECEPTOR ANTAGONISTS IN THE TREATMENT OF DIABETIC NEPHROPATHY | SMITHKLINE BEECHAM PLC (GB) | 1992-06-25 | — | — | WO | disclosed |
| WO-1992010179-A1 | USE OF ANGIOTENSIN II RECEPTOR ANTAGONISTS IN THE TREATMENT OF MACULAR DEGENERATION | SMITHKLINE BEECHAM PLC (GB) | 1992-06-25 | — | — | WO | disclosed |
| WO-1992000068-A1 | SUBSTITUTED HISTIDINES | SMITHKLINE BEECHAM CORPORATION (US) | 1992-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187044-A1 | Medicament | AGTR2, AGTR1, ACE | ACE 3/4885MME 10/4885CPA1 376/4885 |
| US-20030004201-A1 | Medicament | AGTR2, AGTR1, ACE | ACE 3/4885MME 12/4885CPA1 310/4885 |
| US-20030166700-A1 | Administering a substituted imidazoles to a mammal for the treatment of athroma progression and regression | AGTR1, AGTR2, AGT | ACE 6/4885MME 282/4885CPA1 885/4885 |
| US-20030096851-A1 | Medicament | AGTR2, AGTR1, ACE | ACE 3/4885MME 10/4885CPA1 376/4885 |
| US-20030050285-A1 | Substituted imidazoles; angiotensin II receptor antagonist for the treatment of hemorrhagic stroke | AGTR2, AGTR1, ACE | ACE 3/4885MME 24/4885CPA1 1353/4885 |
| US-20030069293-A1 | Medicament | AGTR2, AGTR1, ACE | ACE 3/4885MME 21/4885CPA1 328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.